ClinicalTrials.gg
Not yet recruitingNCT07942818Updated Nov 17, 2026

Clinical Outcomes of the Modified Direct Lateral Approach Versus the Modified Anterolateral Approach in Hip Arthroplasty Performed in the Lateral Decubitus Position

An interventional study of Modified Direct Lateral Approach and Modified Anterolateral Approach in Hip Osteoarthritis, Osteoarthritis, Hip and Hip Disorders, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Assiut University · Not applicable, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this clinical trial is to compare two surgical approaches used during primary hip replacement surgery (hip arthroplasty): the modified direct lateral approach and the modified anterolateral approach. Both surgical approaches are performed while the patient is lying on their side (the lateral decubitus position).

Hip replacement surgery is an established treatment for severe hip joint conditions such as end-stage hip osteoarthritis, helping to reduce pain and improve physical function and quality of life. Different surgical pathways to reach the hip joint interact differently with the surrounding hip abductor muscles, which may affect early recovery, walking ability, and daily physical function.

In this study, 300 adult participants (aged 18 years and older) scheduled for primary total hip replacement or partial hip replacement (hemiarthroplasty) at Assiut University Hospital will be randomly assigned, like flipping a coin, to one of two equal groups:

  • Modified Direct Lateral Approach Group: Participants will undergo hip replacement using the modified Hardinge approach, which reaches the hip joint from the side and involves partially splitting and elevating the front portion of the hip abductor muscle tendon.
  • Modified Anterolateral Approach Group: Participants will undergo hip replacement using the modified Watson-Jones approach, which reaches the hip joint through a natural space between two muscles at the front-side of the hip without splitting the abductor muscle.

Before surgery and at follow-up visits 6 weeks, 3 months, 6 months, and 12 months after surgery, participants will complete the Hip Disability and Osteoarthritis Outcome Score (HOOS) questionnaire to evaluate their ability to perform activities of daily living. Researchers will also examine hip X-rays to check implant positioning and monitor participants for any surgical complications for up to 1 year after surgery.

02

Conditions studied

  • Hip Osteoarthritis
  • Osteoarthritis, Hip
  • Hip Disorders

Browse trials for

Keywords

  • Total Hip Arthroplasty
  • Hip Arthroplasty
  • Direct Lateral Approach
  • Anterolateral Approach
  • Hardinge Approach
  • Watson-Jones Approach
  • Lateral Decubitus Position
  • HOOS
03

In context

Osteoarthritis, Hip

641 studies on the registry are indexed under Osteoarthritis, Hip; 120 are open to participants now.

This study's planned enrollment of 300 is above the median of 90 across 457 interventional studies indexed under Osteoarthritis, Hip.

Browse Osteoarthritis, Hip studies →

Lead sponsor

Assiut University is the lead sponsor of 5,088 studies on the registry; 2,185 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 years or older
  • Indicated for primary hip arthroplasty
  • Ambulatory before surgery, with or without a walking aid
  • Able to understand the study and complete the Hip Disability and Osteoarthritis Outcome Score (HOOS) questionnaire
  • Willing to participate and sign written
  • Able and willing to comply with standardized postoperative rehabilitation

Exclusion criteria

Exclusion Criteria:

  • Previous hip surgery (e.g., first-stage procedure)
  • Developmental hip dysplasia
  • Severe proximal femoral deformity or severe acetabular bone deficiency
  • Ankylosed or severely stiff hip
  • Neurological disorders significantly affecting gait or hip function
  • Cognitive impairment preventing reliable assessment
  • Uncontrolled medical conditions
  • (BMI) greater than 40
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Modified Direct Lateral Approach

    Patients undergoing primary hip arthroplasty (total hip arthroplasty or hemiarthroplasty) via the modified direct lateral (Hardinge) surgical approach performed in the lateral decubitus position.

    Procedure: Modified Direct Lateral Approach

  • Active comparator
    Modified Anterolateral Approach

    Patients undergoing primary hip arthroplasty (total hip arthroplasty or hemiarthroplasty) via the modified anterolateral (Watson-Jones) intermuscular surgical approach performed in the lateral decubitus position.

    Procedure: Modified Anterolateral Approach

Interventions

  • ProcedureModified Direct Lateral Approach

    Primary total hip arthroplasty or hemiarthroplasty performed using the modified direct lateral (Hardinge) surgical approach in the lateral decubitus position. This technique provides direct joint access through the lateral aspect and involves partial splitting and elevation of the anterior portion of the gluteus medius and minimus tendons.

  • ProcedureModified Anterolateral Approach

    Primary total hip arthroplasty or hemiarthroplasty performed using the modified anterolateral (Watson-Jones) surgical approach in the lateral decubitus position. This intermuscular technique enters through the interval between the tensor fasciae latae and gluteus medius to preserve abductor tendon continuity.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hip Disability and Osteoarthritis Outcome Score (HOOS) Activities of Daily Living (ADL) Subscale Score

    The Hip Disability and Osteoarthritis Outcome Score (HOOS 2.0) Activities of Daily Living (ADL) subscale is a validated patient-reported outcome measure assessing functional ability during daily activities. Raw scores are transformed to a 0 to 100 scale, where 0 indicates extreme hip problems and 100 indicates no hip problems. A positive change from baseline represents functional improvement.

    Time frame: Baseline (preoperative) and 12 months postoperatively

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2027, 12 months later.

Of 200 non-industry interventional studies with no phase under Osteoarthritis, Hip, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 45. This study's planned 12 months is below that.

Counting every sponsor, half of 226 studies reached it within 29 months; a quarter within 14 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 17, 2026
StartEst.
Nov 2026
Primary completionEst.
Nov 2027
CompletionEst.
Dec 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07942818
Lead sponsor
Assiut University
Responsible party
Mahmoud Samir Mondy Mehany (Resident, Assiut University) — Principal investigator
First posted
Nov 17, 2026
Start date
Nov 2026 (estimated)
Primary completion
Nov 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 17, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion